Catamaran Bio sets sail in 2022

Interview with Dr Vipin Suri, CSO Catamaran Bio about the science behind their CAR-NK cell therapy.

July 27, 2022

What do the Konami code and targeting KRAS have in common?

A rock around the KRAS clock

July 12, 2022

Shoreline rides the CAR-NK wave at AACR22

First in a mini-series featuring some of the companies that presented CAR-NK cell data at AACR22

July 7, 2022

Winner, winner, chicken dinner!

5 key and novel early areas of development which stood out to us at AACR22

April 11, 2022

A high level view of the latest Target Protein Degradation data

What's the skinny on C4 Therapeutics and other TPD programs at AACR and ASCO?

May 16, 2022

Watch to watch out for at ASCO22

Hot or not - 5 early stage trials with different agents and targets

May 5, 2022

Take the high road

5 abstracts to watch out for at the ASCO22 meeting in Chicago

May 2, 2022


New CAR-T cell developments in solid tumours - hit or miss?

April 24, 2022

An inconvenient truth

Looking beyond the hype from a broader perspective

April 18, 2022

AACR22 Part 2 of the RASpalooza

Highlights from the KRAS front with three different company products not named sotorasib or adagrasib

April 13, 2022

An explosion of new opportunities in the expanding KRAS landscape

Going beyond both G12C and G12D to a plethora of new targets and combination approaches

April 10, 2022

Addressing acquired resistance through novel combination strategies

All aboard to hear more about novel targeted therapy combination strategies...

April 8, 2022

Discovering novel oncogenic targets

Finding new synthetic lethal targets to induce more potent cell death and improve outcomes

April 8, 2022

Off the beaten track in the bispecific landscape

Everything you needed to know about bispecifics at AACR22 and more!

March 31, 2022

What to watch at AACR22 on NK cells

What to watch out for at AACR22 if you're interested in NK cells

March 29, 2022

5 important topics to watch out for at AACR22 on bispecifics

5 areas to watch out for on the bispecific antibody front

March 25, 2022

New directions and opportunities with intractable oncology targets

Just because a pathway has been called undruggable doesn't always mean it will be so!

March 15, 2022

AACR22 Preview 1 – Key topics to watch out for

Hot topics to follow at AACR22

March 7, 2022